# A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

> **NCT02545543** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 2278 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Seqirus QIV
- **BIOLOGICAL:** Comparator QIV

## Key facts

- **NCT ID:** NCT02545543
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-01
- **Final completion:** 2016-06
- **Target enrollment:** 2278 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545543, "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02545543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*